Inventor · disambiguated record
John David Harling
Also filed as: HARLING JOHN D · HARLING JOHN DAVID
21 granted patents·16 pending applications·211 citations·filing 1994–2024
95Inventor score
Files withSMITHKLINE BEECHAM PLC13GLAXOSMITHKLINE IP DEV LTD9SMITHKLINE BEECHAM CORP3UNIV YALE3ALDER CATHERINE MARY1
Top patents by PatentIndex Score
37 records- 0197US10336744B21AP E3 ligase directed proteolysis targeting chimeric moleculesGLAXOSMITHKLINE IP DEV LTD·Filed 2016·Granted Jul 2, 2019·50 cites·2 claims
- 0291US10730862B2Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligaseUNIV YALE·Filed 2013·Granted Aug 4, 2020·15 cites·14 claims
- 0389US9988376B2Benzothiophene derivatives as estrogen receptor inhibitorsGLAXOSMITHKLINE IP DEV LTD·Filed 2014·Granted Jun 5, 2018·9 cites·21 claims
- 0487US9993514B2CompoundsGLAXOSMITHKLINE IP DEV LTD·Filed 2014·Granted Jun 12, 2018·11 cites·12 claims
- 0580US6906089B2Triarylimidazole derivatives as cytokine inhibitorsSMITHKLINE BEECHAM CORP·Filed 2001·Granted Jun 14, 2005·15 cites·9 claims
- 0676US6492388B1Substituted isoquinoline derivatives and their use as inticonvulsantsSMITHKLINE BEECHAM PLC·Filed 2000·Granted Dec 10, 2002·7 cites·14 claims
- 0776US5817698ASubstituted cycloalkylamine derivatives and their use as calcium channel antagonistsSMITHKLINE BEECHAM PLC·Filed 1995·Granted Oct 6, 1998·40 cites·13 claims
- 0875US10781205B2Conjugates comprising RIPK2 inhibitorsGLAXOSMITHKLINE IP DEV LTD·Filed 2017·Granted Sep 22, 2020·1 cites·9 claims
- 0974US2024317729A1Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin LigaseUNIV YALE·Filed 2024·Application pending·0 cites
- 1072US10435391B2CompoundsGLAXOSMITHKLINE IP DEV LTD·Filed 2016·Granted Oct 8, 2019·1 cites·6 claims
- 1167US5863952AEnantiomers of 1-(3,4-dichlorobenzyl)-2-methylaminoindaneSMITHKLINE BEECHAM PLC·Filed 1996·Granted Jan 26, 1999·22 cites·10 claims
- 1261US6110934ASubstituted benzamide derivatives and their use as anticonvulsantsSMITHKLINE BEECHAM PLC·Filed 1997·Granted Aug 29, 2000·8 cites·20 claims
- 1359US2019382381A1Novel compoundsGLAXOSMITHKLINE IP DEV LTD·Filed 2019·Application pending·0 cites
- 1458US7235544B23-sulfonylamino-pyrrolidine-2-one derivatives as inhibitors of factor XaGLAXO GROUP LTD·Filed 2004·Granted Jun 26, 2007·1 cites·8 claims
- 1558US7105536B2CompoundsSMITHKLINE BEECHAM PLC·Filed 2004·Granted Sep 12, 2006·0 cites·4 claims
- 1658US6762192B2Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activitySMITHKLINE BEECHUM P L C·Filed 2002·Granted Jul 13, 2004·1 cites·6 claims
- 1756US5773463AIndane and tetrahydronaphthalene derivatives as calcium channel antagonistsSMITHKLINE BEECHAM PLC·Filed 1994·Granted Jun 30, 1998·11 cites·17 claims
- 1855US6770657B2CompoundsSMITHKLINE BEECHAM PLC·Filed 2002·Granted Aug 3, 2004·0 cites·4 claims
- 1954US2019127359A1Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin LigaseUNIV YALE·Filed 2018·Application pending·0 cites
- 2052US2019263798A1Novel compoundsGLAXOSMITHKLINE IP DEV LTD·Filed 2019·Application pending·0 cites
- 2150US2004220230A1PyridinylimidazolesSMITHKLINE BEECHAM PLC·Filed 2004·Application pending·0 cites
- 2247US6245778B11,6-naphthyridine anti-convulsantsSMITHKLINE BEECHAM PLC·Filed 1998·Granted Jun 12, 2001·8 cites·7 claims
- 2346US6277861B1Anti-convulsant isoquinolyl-benzamide derivativesSMITHKLINE BEECHAM PLC·Filed 1998·Granted Aug 21, 2001·6 cites·20 claims
- 2446US2019152946A1Novel CompoundsGLAXOSMITHKLINE IP DEV LTD·Filed 2017·Application pending·0 cites
- 2543US2009099231A13-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa InhibitorsHARLING JOHN DAVID·Filed 2006·Application pending·0 cites
- 2642US7199239B2Chemical compoundsSMITHKLINE BEECHAM CORP·Filed 2003·Granted Apr 3, 2007·0 cites·12 claims
- 2741US6492378B1Substituted isoquinoline derivatives and their use as anticonvulsivantsSMITHKLINE BEECHAM PLC·Filed 1999·Granted Dec 10, 2002·4 cites·8 claims
- 2841US2007249705A1N-(1-(2,3-Dihydro-1H-Inden-5Yl)-2-Oxo-3-Pyrrolidinyl)-Sulfonamide Derivatives for Use as Factor Xa InhibitorsHARLING JOHN D·Filed 2005·Application pending·0 cites
- 2941US2004266842A1Thiazolyl substituted triazoles as alk5 inhibitorsGASTER LARAMIE MARY·Filed 2002·Application pending·0 cites
- 3041US2005014938A1Phenyl substituted triazoles and their use as selective inhibitors of akl5 kinaseFiled 2002·Application pending·0 cites
- 3141US2019210996A1Novel compoundsGLAXOSMITHKLINE IP DEV LTD·Filed 2017·Application pending·0 cites
- 3239US2004152738A1Pyridyl-substituted triazoles as tgf inhibitorsFiled 2001·Application pending·0 cites
- 3339US2008306045A11-Benzazepine-3-Sulfonylamino-2-Pyrroridones as Factor Xa InhibitorsCAMUS LAURE·Filed 2006·Application pending·0 cites
- 3436US2007155805A1Benzofuran and bezothiophene derivatives useful for the treatment of cardiovascular diseaseSMITHKLINE BEECHAM CORP·Filed 2005·Application pending·0 cites
- 3535US2001025045A1Substituted isoquinoline derivatives and their use as anticonvulsantsSMITHKLINE BEECHAM PLC·Filed 2001·Application pending·0 cites
- 3634US6410555B1Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activitySMITHKLINE BEECHAM PLC·Filed 1999·Granted Jun 25, 2002·1 cites·4 claims
- 3728US2012058984A1Pyrimidine derivatives used as itk inhibitorsALDER CATHERINE MARY·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when John David Harling files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →